Добірка наукової літератури з теми "Hepatitis G virus Victoria"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Hepatitis G virus Victoria".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Hepatitis G virus Victoria"
Reshetnyak, Vasiliy Ivanovich, Tatiana Igorevna Karlovich, and Ljudmila Urievna Ilchenko. "Hepatitis G virus." World Journal of Gastroenterology 14, no. 30 (2008): 4725. http://dx.doi.org/10.3748/wjg.14.4725.
Повний текст джерелаPatrick, Christian C. "HEPATITIS G VIRUS." Pediatric Infectious Disease Journal 17, no. 11 (November 1998): 1045–46. http://dx.doi.org/10.1097/00006454-199811000-00017.
Повний текст джерелаVersalovic, James. "Hepatitis G virus." Clinical Microbiology Newsletter 19, no. 21 (November 1997): 161–64. http://dx.doi.org/10.1016/s0196-4399(00)89182-5.
Повний текст джерелаFairley, Christopher K., David E. Leslie, Suellen Nicholson, and Ian D. Gust. "Epidemiology and hepatitis C virus in Victoria." Medical Journal of Australia 153, no. 5 (September 1990): 271–73. http://dx.doi.org/10.5694/j.1326-5377.1990.tb136899.x.
Повний текст джерелаShadur, B., J. MacLachlan, and B. Cowie. "Hepatitis D virus in Victoria 2000-2009." Internal Medicine Journal 43, no. 10 (October 2013): 1081–87. http://dx.doi.org/10.1111/imj.12247.
Повний текст джерелаKew, Michael C., and Chris Kassianides. "HGV: hepatitis G virus or harmless G virus?" Lancet 348 (December 1996): S10. http://dx.doi.org/10.1016/s0140-6736(96)98020-4.
Повний текст джерелаKarayiannis, P., J. Pickering, M. Chiaramonte, and HC Thomas. "Hepatitis G virus infection." Lancet 349, no. 9056 (March 1997): 954. http://dx.doi.org/10.1016/s0140-6736(05)62732-8.
Повний текст джерелаSchleicher, Sabine, Andrea Normann, Michael Gregor, Georg Hess, and Bertram Flehmig. "Hepatitis G virus infection." Lancet 349, no. 9056 (March 1997): 954–55. http://dx.doi.org/10.1016/s0140-6736(05)62733-x.
Повний текст джерелаRobert Halasz, Ola Weiland, Matti S. "GB Virus C/Hepatitis G Virus." Scandinavian Journal of Infectious Diseases 33, no. 8 (January 2001): 572–80. http://dx.doi.org/10.1080/00365540110027123.
Повний текст джерелаKiyosawa, Kendo, and Eiji Tanaka. "GB Virus C/Hepatitis G Virus." Intervirology 42, no. 2-3 (1999): 185–95. http://dx.doi.org/10.1159/000024979.
Повний текст джерелаДисертації з теми "Hepatitis G virus Victoria"
Halasz, Robert. "Epidemiology and clinical importance of GB virus C/hepatitis G virus /." Stockholm, 2000. http://diss.kib.ki.se/2000/91-628-3997-7/.
Повний текст джерелаCuceanu, Narcisa Manuela. "Structural and genetic analysis of hepatitis G virus/GB virus-C." Thesis, University of Edinburgh, 1999. http://hdl.handle.net/1842/22126.
Повний текст джерелаSentjens, Roel Emiel Johannus Henricus. "New developments in hepatitis B, C and G virus." [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host], 2003. http://dare.uva.nl/document/87188.
Повний текст джерелаBerg, Thomas. "Chronische Hepatitis C." Doctoral thesis, Humboldt-Universität zu Berlin, Medizinische Fakultät - Universitätsklinikum Charité, 2002. http://dx.doi.org/10.18452/13812.
Повний текст джерелаThe major goal of this thesis is the analysis of the clinical outcome of patients with Hepatitis C virus (HCV) infection and the response to therapy. Analysed were 1. different types of therapeutic strategies 2. causes responsible for ineffective antiviral therapy (non-response) 3. clinical relevance of the newly discovered hepatitis-associated viruses and 4. the role of these viruses in patients with acute or chronic hepatitis of unknown causes and in those receiving liver grafts. Ad 1. Compared were different therapeutic concepts such as short-term combination therapy, triple-therapy, high dose IFN?-therapy and the use of antiviral substances such as ribavirin and amantadine. It emerged that relevant prognostic parameters can be deduced with respect to the therapeutic response rate. Ad 2. Analysed were possible molecular mechanisms, which may interfere with response or non-response to antiviral therapy. In this respect, we focussed on the interaction of certain HCV-proteins as NS5A, E2, so-called PKR-eIF2a phosphorylisation-homology-domain (PePHD). with the interferon-?-induced effector proteins. There is evidence, that number of mutations within the NS5A proteins are of prognostic relevance with respect to the response to interferon?-therapy. In contrast, mutations within the PePHD-region do not play any role in this respect. Ad 3. We also studied the clinical relevance of the newly discovered viruses GBV-C/HGV and TTV, and found, that they have no impact concerning the course of chronic hepatitis C. These viruses are interferon-sensitive and do not influence the IFNa-response as it could be documented by following the course of co-infected patients. Ad 4. Our studies also focused on the prevalence, transmission and relevance of GBV-C/HGV and TTV infections with respect to their role as hepatitis-inducing agents. We can show that both virus types are parenterally transmitted. There is a high prevalence for both types in patients confronted with risk factors for parenteral factors. From analysis of many patients being chronically infected with these viruses it became quite clear that they lack any important potency to provoke chronic liver disease.
Tucker, Timothy Johan Paul. "Epidemiology, molecular characterisation and tropism of the Hepatitis G Virus / GBV-C." Doctoral thesis, University of Cape Town, 1999. http://hdl.handle.net/11427/25669.
Повний текст джерелаISHIKAWA, TETSUYA. "IMMUNOREGULATION OF HEPATITIS B VIRUS INFECTION : RATIONALE AND CLINICAL APPLICATION." Nagoya University School of Medicine, 2012. http://hdl.handle.net/2237/16732.
Повний текст джерелаLarios, Paterna Cristina. "Péptidos de fusión del virus de la hepatitis G: definición, síntesis y caracterización biofísica." Doctoral thesis, Universitat de Barcelona, 2006. http://hdl.handle.net/10803/1806.
Повний текст джерелаdescritos hasta el momento, se encuentran en la zona interna de la proteína estructural.
El virus de la hepatitis G se asemeja estructuralmente al virus de la hepatitis C, por ello,la búsqueda del péptido de fusión se centró en la proteína estructural E2 también presente en el virus de la hepatitis C. Las regiones escogidas dentro de la proteína estructural pertenecen a la región amino terminal, E2(7-26), y la zona interna (E2(279-298).
Estas secuencias fueron sintetizadas mediante metodología en fase sólida y se estudió la
interacción entre los péptidos y modelos de membrana de distinta complejidad (monocapas lipídicas, bicapas lipídicas). Las técnicas utilizadas para conocer la interacción entre ambos fueron las isotermas de Langmuir, la calorimetría diferencial de barrido, la espectroscopia de fluorescencia, la espectroscopia de UV y la microscopía.
Además se estudió la conformación adoptada por los péptidos por las técnicas de dicroísmo circular y espectroscopia de infrarrojos por transformada de Fourier. De todos los resultados obtenidos el péptido que interaccionó en mayor medida con los modelos de membrana, además de desestabilizar y producir fusión fue E2(279-298). Este péptido producía un cambio en su conformación al interaccionar con membranas fosfolipídicas(sobre todo en presencia de cargas negativas) hacia una estructura de tipo alfa-hélice. Este cambio hacia una estructura más ordenada podría proporcionar la conformación activa del péptido responsable de la desestabilización de las membranas.
The hepatitis G virus (GBV-C/HGV) is a enveloped RNA virus belonging to the "Flaviviridae" family. The natural history of the GBV-C/HGV infection is at present not fully understood and its potential to cause hepatitis in humans is questionable.
Elucidation of the mechanism of the fusion of enveloped viruses to target membranes has attracted considerable attention because of its relative simplicity and potential clinical importance. Apart from the functions of viral binding to target membranes and the activation of viral fusion proteins, usually only one viral protein is responsible for the membrane fusion step. However, the nature of the interaction of viral fusion proteins with membranes and the mechanism by which these proteins accelerate the formation of membrane fusion intermediates are poorly understood. In this sense, specialized
hydrophobic conserved domains ("fusion peptides") have been postulated to be absolutely required for the fusogenic activity.
The main objective of the present work was the knowlegment of the fusion peptide of the hepatitis G virus. For this purpose we have performed studies with different synthetic peptides belonging the envelope protein E2 of hepatitis G virus. The selected peptides were from the amino terminal part of the protein (E2(7-26)) and from the internal part (E2(279-298)). We have analysed lipid-peptide interactions depending on the degree of complexity of model membranes: monolayer studies (surface activity,
insertion of peptides into monolayers) and liposomes studies (differential scanning
calorimetry, fluorescence measurements). The peptides were compared for their ability
to interact and perturb membranes. In addition, they were also tested for their ability to
induce both leakage of vesicular contents and vesicle fusion as well as to lyse erythrocytes. Furthermore, we have studied the conformational behaviour of the peptides in water and in different membrane environments by Fourier-transform infrared spectroscopy (FTIR) and circular dichroism (CD). The results obtained showed that the E2(279-298) sequence was able to interact, penetrate and permeabilize vesicles
bilayers in a higher extent than E2(7-26) sequence. Furthermore, the interaction with
membranes induced a change in the internal peptide to an alpha-helical conformation while
the amino terminal sequence did not. This indicate that this internal segment peptide
could be involved in the fusion of hepatitis G virus into cell membrane.
Alay, Romero Maria Teresa. "Estudis fisicoquímics de diferents seqüències peptídiques del virus de l’Hepatitis G." Doctoral thesis, Universitat de Barcelona, 2015. http://hdl.handle.net/10803/285310.
Повний текст джерелаLai, Agnes Suet Wah. "Hepatitis C and G virus infection and non-Hodgkin lymphoma in a case-control study from British Columbia, Canada." Thesis, University of British Columbia, 2007. http://hdl.handle.net/2429/31732.
Повний текст джерелаMedicine, Faculty of
Graduate
Pérez, Escoda María Teresa. "Diseño y síntesis de péptidos para el diagnóstico de la infección por el virus de la hepatitis G (GBV-C/HGV)." Doctoral thesis, Universitat de Barcelona, 2007. http://hdl.handle.net/10803/1807.
Повний текст джерелаDesde hace años, los péptidos sintéticos se vienen utilizando en sistemas de diagnóstico para muchas enfermedades, sin embargo, los péptidos lineales que mimetizan epítopos B son débilmente reconocidos por los anticuerpos, y por ello, existe la tendencia de utilizar combinaciones más complejas que permitan mejorar tanto la sensibilidad como la especificidad de los ensayos.
En esta tesis se han diseñado y sintetizado, utilizando la metodología de síntesis en fase sólida, construcciones peptídicas en las que se combinan regiones de proteínas de envoltura y no estructurales. Se han sintetizado tanto péptidos quiméricos, que contienen más de un epítopo (lineales y ramificados), como péptidos cíclicos en los que los epítopos sufren restricción de movilidad.
La capacidad antigénica de las construcciones sintéticas se ha evaluado utilizando principalmente la técnica del enzimoinmunoensayo (ELISA) aunque también se ha investigado la utilidad de la técnica de la resonancia del plasmón de superficie (SPR) para detectar la presencia de anticuerpos anti-GBV-C/HGV en muestras de suero de individuos pertenecientes tanto a los grupos de riesgo como en la población sana. Además, se ha realizado un estudio conformacional con la finalidad de establecer una correlación entre la estructura secundaria adoptada por los péptidos y su capacidad antigénica. Finalmente, se ha estudiado la capacidad inmunogénica de las construcciones peptídicas en animales de experimentación.
Los resultados obtenidos muestran, por un lado, que las construcciones en las que se combinan varios epítopos son las que presentan una mejor precisión diagnóstica, y por otro lado, que la introducción de restricción de movilidad permite incrementar la sensibilidad mostrada por la molécula precursora lineal.
"Design and synthesis of peptides for serodiagnose of the hepatitis G virus (GBV-C/HGV) infection".
The GB virus C, so called hepatitis G virus (GBV-C/HGV), is a single-strand RNA virus belonging to the Flaviviridae family. The prevalence rate of GBV-C/HGV in healthy blood donors is 1-4% in worldwide and about 20-35% in high risk populations, thus indicating that this virus is transmitted via the parenteral route. Although controversial data exit concerning the potential to cause hepatitis in humans recent studies suggest that coinfection with HIV is associated with prolonged survival. For this reason it would be interesting to find an easy tool to diagnose this apparently non-pathogenic virus.
In recent years, synthetic peptides that mimic specific epitopes of infectious agents have been used in diagnostic systems for various diseases. The main drawback of this approach is that peptides representing topographic B-cell epitopes are poorly recognised by antibodies. There is a tendency toward using chimeric to avoid those problems and to improve the sensitivity and specificity of the assays.
In this thesis, new putative epitopes located both in envelope and in nonstructural proteins of GBV-C/HGV were synthesized using solid-phase chemistry. The corresponding synthetic peptides, obtained in linear, multimeric and cyclic forms, were used as antigens in ELISA and in real-time bioespecific interaction measurements (SPR) to detect GBV-C/HGV-specific antibodies in different panels of human sera. Furthermore, CD and FT-IR have been used in conjunction to characterize the conformational changes therein with synthetic constructs that could explain their different antigenicity.
The results obtained showed, on one hand, that the combination of different antigens seems to be necessary to ensure good sensitivity and more specificity and, on the other hand, that cyclic compounds show higher ability to recognize anti-GBV-C/HGV antibodies than its parent peptide. Our results offer a new approach to develop new diagnostic peptide based biosensors for serodiagnosis of GBV-C/HGV infection.
Частини книг з теми "Hepatitis G virus Victoria"
Ehling, A., B. Gierten, and T. Arndt. "Hepatitis G-Virus (HGV/GBV-C)." In Lexikon der Medizinischen Laboratoriumsdiagnostik, 1–2. Berlin, Heidelberg: Springer Berlin Heidelberg, 2018. http://dx.doi.org/10.1007/978-3-662-49054-9_1432-1.
Повний текст джерелаEhling, A., B. Gierten, and T. Arndt. "Hepatitis G-Virus (HGV/GBV-C)." In Springer Reference Medizin, 1101. Berlin, Heidelberg: Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-48986-4_1432.
Повний текст джерелаUhle, C., A. Huth-Kühne, R. Seelig, T. Goeser, and R. Zimmermann. "Prävalenz and Virusinaktivierung des Hepatitis-G-Virus." In 28. Hämophilie-Symposion Hamburg 1997, 271–73. Berlin, Heidelberg: Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-59915-6_41.
Повний текст джерелаBagasra, Omar, Muhammad Sheraz, and Donald Gene Pace. "Hepatitis G Virus or GBV-C: A Natural Anti-HIV Interfering Virus." In Viruses: Essential Agents of Life, 363–88. Dordrecht: Springer Netherlands, 2012. http://dx.doi.org/10.1007/978-94-007-4899-6_18.
Повний текст джерелаSeifried, E., H. Bialleck, H. Weber, E. Waschk, S. Marx, S. Tschauder, and W. K. Roth. "Die Prävalenz des GB-Virus-C/Hepatitis-G-Virus in Blutspenden und seine Übertragung auf Empfänger." In 27. Hämophilie-Symposion Hamburg 1996, 54–58. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-80403-8_9.
Повний текст джерелаNübling, M., and J. Löwer. "GB-C/Hepatitis G Virus bei Hämophilen, Dialysepatienten, HIV-Infizierten und sein Nachweis in Blutprodukten." In 27. Hämophilie-Symposion Hamburg 1996, 47–53. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-80403-8_8.
Повний текст джерела"Hepatitis G Virus (HGV)." In Lexikon der Infektionskrankheiten des Menschen, 387. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-39026-8_456.
Повний текст джерела"Antikörper gegen Hepatitis-G-Virus." In Springer Reference Medizin, 158. Berlin, Heidelberg: Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-48986-4_310247.
Повний текст джерелаCramp, Matthew, Ashwin Dhanda, and Nikolai V. Naoumov. "Hepatitis viruses (excluding hepatitis C virus)." In Oxford Textbook of Medicine, edited by Christopher P. Conlon, 889–96. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198746690.003.0096.
Повний текст джерелаRizza, Stacey A. "Viral Hepatitis." In Mayo Clinic Infectious Diseases Board Review, 295–300. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199827626.003.0030.
Повний текст джерелаТези доповідей конференцій з теми "Hepatitis G virus Victoria"
Al-absi, Enas, Nadima Haj Ali, Aisha Khan, Makiyeh Khalili, Tameem Hadwan, Naema Al-mawlawi, Raed Abuodeh, and Gheyath Khalid Nasrallah. "Infection Rates And Phylogenetic Analysis Of Hepatitis G Virus (hgv)/gb Virus C (gbv-c) Among Qatari Blood Donors." In Qatar Foundation Annual Research Conference Proceedings. Hamad bin Khalifa University Press (HBKU Press), 2014. http://dx.doi.org/10.5339/qfarc.2014.hbop0582.
Повний текст джерела"SECRETOS DE OFICIO DEL DULCERX." In 23° Congreso de la Sociedad Española de Patología Dual (SEPD) 2021. SEPD, 2021. http://dx.doi.org/10.17579/sepd2021o039.
Повний текст джерела